Aurobindo receives 9th approval from MCC South Africa

RELATED NEWS Sell Aurobindo Pharma: Motilal Oswal Aurobindo Q4 PAT seen up 51% to Rs 565mn: Motilal Oswal Stocks in news: Sun TV, Shoppers Stop, Aurobindo ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 13/02/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is delighted to announce that it has received another marketing authorization approval from Medicines Control Council (MCC) of South Africa. The Council has approved Citalopram tablets in 20mg strength. South African market is highly regulated and very important in its Geographical sphere. Aurobindo having got this approval can now participate in CNS segment of South African market, which is a fast growing sector.

 

Citalopram is popularly known as Celexa and marketed by Forest Laboratories. Citalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors. It is mostly used in symptoms of depression but is also prescribed in some forms of anxiety like social anxiety and premenstrual dysphoric disorder. The company is successfully marketing Citalopram in US and Canada.

 

Citalopram today commands a market of 56mio USD in South Africa. 

 

Sourced From: Aurobindo Pharma Limited